Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$73.51 USD
+0.21 (0.29%)
Updated Jul 18, 2024 04:00 PM ET
After-Market: $73.37 -0.14 (-0.19%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$73.51 USD
+0.21 (0.29%)
Updated Jul 18, 2024 04:00 PM ET
After-Market: $73.37 -0.14 (-0.19%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Zacks News
New Strong Sell Stocks for March 12th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Gilead (GILD) Announces Positive Long-Term Results on Descovy
by Zacks Equity Research
Gilead (GILD) announces long-term results from the DISCOVER study, which showed that Descovy is effective for HIV prevention with non-inferior efficacy to Truvada.
Biotech Stock Roundup: NVAX, CANF Up on Coronavirus Treatment Updates & More
by Zacks Equity Research
The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.
Can-Fite (CANF) to Explore RA Drug for Coronavirus Treatment
by Zacks Equity Research
Can-Fite (CANF) announces plans to explore piclidenoson for the treatment of coronavirus.
Regeneron (REGN) Gains from Focus on Coronavirus Treatments
by Zacks Equity Research
Regeneron's (REGN) shares grow year to date owing to focus on developing a treatment for combating the novel coronavirus.
Why Is Gilead (GILD) Up 15.4% Since Last Earnings Report?
by Zacks Equity Research
Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Alnylam, Vir Collaborate on RNAi Therapy for Coronavirus
by Zacks Equity Research
Alnylam (ALNY) expands its collaboration pact with Vir Biotechnology to develop RNAi therapeutics targeting SARS-CoV-2, the virus that induces Covid-19. Stock gains.
Inovio Surges on Expedited Timeline for Coronavirus Vaccine
by Zacks Equity Research
Inovio (INO) to initiate human clinical studies on INO-4800, its DNA vaccine, this April, for the treatment of the deadly coronavirus. The stock price shoots up.
Biotech Stock Roundup: GILD to Buy Forty Seven, Pipeline Updates From BIIB & More
by Zacks Equity Research
The biotech sector was in focus with new drug approvals, acquisitions and regular pipeline updates from quite a few companies.
Are Options Traders Betting on a Big Move in Gilead (GILD) Stock?
by Zacks Equity Research
Investors need to pay close attention to Gilead (GILD) stock based on the movements in the options market lately.
Gilead to Buy Immuno-Oncology Company Forty Seven for $4.9B
by Zacks Equity Research
Gilead (GILD) looks to strengthen its immuno-oncology research and development portfolio with the acquisition of Forty Seven.
Trump Asks Pharma Firms to Step Up Coronavirus Vaccine Work
by Kinjel Shah
President Donald Trump asks pharmaceutical companies working on making vaccines or treatments for coronavirus to accelerate development.
Pfizer Plans Coronavirus Therapy, Progresses With Tanezumab BLA
by Zacks Equity Research
Pfizer (PFE) identifies potential antiviral compounds to develop a treatment for coronavirus disease. The FDA accepts regulatory application seeking approval for tanezumab for osteoarthritis.
5 Biotechs That Escaped the Coronavirus Onslaught Last Week
by Kinjel Shah
Here we discuss 5 biotech stocks that outperformed the industry amid the U.S. market slump.
These 6 Drug Companies are Testing a Coronavirus Vaccine
by Madeleine Johnson
As the coronavirus outbreak continues to spread, some of the biggest drug companies are moving closer to finding a vaccine.
These 6 Drug Companies are Testing a Coronavirus Vaccine
by Madeleine Johnson
As the coronavirus outbreak continues to spread, some of the biggest drug companies are moving closer to finding a vaccine.
Gilead Sciences (GILD) Surges: Stock Moves 6.6% Higher
by Zacks Equity Research
Gilead Sciences (GILD) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
5 Drug/Biotech Stocks Likely to Beat Q4 Earnings Estimates
by Zacks Equity Research
Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the fourth quarter.
Bristol-Myers' (BMY) CAR T Cell Therapy Gets Priority Review
by Zacks Equity Research
Bristol-Myers' (BMY) BLA for lisocabtagene maraleucel gets Priority Review from the FDA.
J&J (JNJ) Signs Deal With HHS to Develop Coronavirus Vaccine
by Zacks Equity Research
Johnson & Johnson (JNJ) expands its agreement with BARDA, part of U.S. Department of Health and Human Services for accelerated development of a vaccine for the newly found coronavirus.
Can Biotech ETFs Gain on Mixed Q4 Earnings Results?
by Sweta Jaiswal, FRM
Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their Q4 earnings releases.
Western Union (WU) Q4 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Western Union (WU) delivered earnings and revenue surprises of -11.63% and -1.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
VAREX IMAGING (VREX) Q1 Earnings Miss Estimates
by Zacks Equity Research
VAREX IMAGING (VREX) delivered earnings and revenue surprises of -25.00% and 4.87%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Diodes (DIOD) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Diodes (DIOD) delivered earnings and revenue surprises of 3.17% and 0.39%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Gilead's BLA for CAR T Cell Therapy Gets FDA Acceptance
by Zacks Equity Research
The FDA accepts Gilead's (GILD) BLA for its second CAR T cell therapy, KTE-X19.